Irinotecan
What's New
Last Posted: Apr 22, 2021
- Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting.
Luczak Tiana S et al. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021 10781552211005529 - Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
Reizine Natalie et al. Therapeutic advances in medical oncology 2020 121758835920974118 - Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.
Jensen Benny V et al. International journal of cancer 2020 Dec - Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
Marks Eric I et al. American journal of clinical oncology 2020 Dec - Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.
Hulshof Emma C et al. European journal of cancer (Oxford, England : 1990) 2020 Oct 1419-20 - Prognosis and personalized treatment prediction in TP53-mutant hepatocellular carcinoma: an in silico strategy towards precision oncology.
Yang Chen et al. Briefings in bioinformatics 2020 Aug - Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Lenz Heinz-Josef et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 37(22) 1876-1885 - Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.
Wei XiaoXia et al. Pharmacogenomics 2019 20(4) 241-249 - UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.
Etienne-Grimaldi Marie-Christine et al. Fundamental & clinical pharmacology 2015 29(3) 219-37 - Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man Femke M et al. Clinical pharmacokinetics 2018 57(10) 1229-1254
More
About PGx PHGKB
PGx PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to medications....more
Content Summary
- COVID-19 (1)
- Human Genome Epidemiologic Studies (496)
- GWAS Studies (2)
- Human Genomics Translation/Implementation Studies (27)
- Genomic Tests Evidence Synthesis (10)
- Genomic Tests Guidelines (3)
- Tier-Classified Guidelines (1)
- Non-Genomics Precision Health (1)
- State Public Health Genomics Programs (1)
- Reviews/Commentaries (15)
Common PGx Related Topics
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Oct 1, 2020
- Page last updated:Apr 26, 2021
- Content source: